MET and breast cancer: We characterized the extent of signaling complexity and cross-talk between simultaneous treatments with multiple HER family and c-Met agonists and antagonists in live tumor cell samples obtained from three different primary breast cancer patient tumor specimens and show very strong synergy between the simultaneous combined pan-HER and c-Met inhibition.